Avadel Pharmaceuticals plc

Total Valuation

Avadel Pharmaceuticals plc carries a market capitalization of 2.12B, placing it among publicly traded companies globally. Its enterprise value stands at 1.39B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Avadel Pharmaceuticals plc currently has 97.24M shares outstanding.

Valuation Ratios

The price-to-sales ratio is 5.94, and the price-to-book ratio stands at -1.87.

Enterprise Valuation

On an enterprise value basis, Avadel Pharmaceuticals plc trades at an EV/EBITDA multiple of 169.25 and an EV/FCF ratio of 39.22. The EV/Sales ratio of 5.58 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 306.81 provides insight into valuation relative to core operating earnings.

Financial Position

Avadel Pharmaceuticals plc maintains a current ratio of 2.76, meaning it holds 2.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 2.60, indicating elevated leverage, while an interest coverage ratio of 0.84 demonstrates limited ability to service its debt obligations.

Financial Efficiency

Taxes

Over the trailing twelve months, Avadel Pharmaceuticals plc has paid -2.98M in income taxes, reflecting an effective tax rate of 62.96.

Stock Price Statistics

Avadel Pharmaceuticals plc's stock has gained approximately 144.79638% over the past 52 weeks. The 50-day moving average sits at 21.50, while the 200-day moving average is 15.49.

Income Statement

Over the trailing twelve months, Avadel Pharmaceuticals plc generated 248.52M in revenue and converted that into -278,000.00 in net income, yielding earnings per share of 0.00. EBITDA reached 8.20M, while operating income came in at 4.52M.

Balance Sheet

Avadel Pharmaceuticals plc holds 91.58M in cash and equivalents against 2.55M in total debt, resulting in a net debt position of -79.81M. Total book value stands at -788.59M, with working capital of 109.74M providing operational flexibility.

Cash Flow

Avadel Pharmaceuticals plc produced 34.54M in operating cash flow over the past twelve months. After subtracting -9,000.00 in capital expenditures, free cash flow totaled 34.53M - equivalent to 0.36 per share.

Margins

Avadel Pharmaceuticals plc operates with a gross margin of 94.91, reflecting its pricing power and cost economics. The operating margin of 1.82 and net profit margin of -0.11 provide insight into operational efficiency.

Dividends & Yields

Scores

Avadel Pharmaceuticals plc posts an Altman Z-Score of 4.86, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.